CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	DeepHealth, Inc.	Unregistered Securities	Total Radnet, Inc.'s Equity	Total Radnet, Inc.'s Equity Unregistered Securities	Common Stock	Common Stock DeepHealth, Inc.	Common Stock Unregistered Securities	Additional Paid-In Capital	Additional Paid-In Capital Unregistered Securities	Accumulated Other Comprehensive Loss	Accumulated Deficit	Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2021						53,548,227
Beginning balance at Dec. 31, 2021	$ 346,157			$ 228,904		$ 5			$ 342,592		$ (20,421)	$ (93,272)	$ 117,253
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under the equity compensation plan (in shares)						685,577	973,144
Stock-based compensation expense	18,856			18,856					18,856
Issuance of common stock in connection with acquisitions (in shares)								2,106,292
Issuance of common stock in connection with acquisitions			$ 56,470		$ 56,470					$ 56,470
Forfeiture of restricted stock (in shares)						(22,484)
Forfeiture of restricted stock	(45)			(45)					(45)
Sale of economic interests in majority owned subsidiary, net of taxes	6,498			6,498					6,498
Contributions from noncontrolling partner	11,077			0									11,077
Change in cumulative foreign currency translation adjustment	(12,031)			(12,031)							(12,031)
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	2,771			2,771							2,771
Other	(3)			(2)					(2)		1	(1)	(1)
Net income (loss)	28,640			11,585								11,585	17,055
Ending balance (in shares) at Sep. 30, 2022						57,290,756
Ending balance at Sep. 30, 2022	458,390			313,006		$ 5			424,369		(29,680)	(81,688)	145,384
Beginning balance (in shares) at Jun. 30, 2022						57,303,565
Beginning balance at Jun. 30, 2022	451,385			312,183		$ 5			419,136		(24,603)	(82,355)	139,202
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under the equity compensation plan (in shares)						2,500	7,175
Stock-based compensation expense	3,362			3,362					3,362
Adjustment for shares returned/forfeited (in shares)						(22,484)
Adjustment for shares returned/forfeited	(45)			(45)					(45)
Sale of economic interests in majority owned subsidiary, net of taxes	1,916			1,916					1,916
Contributions from noncontrolling partner	404			0									404
Change in cumulative foreign currency translation adjustment	(6,000)			(6,000)							(6,000)
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	924			924							924
Other	(3)			(2)							(1)	(1)	(1)
Net income (loss)	6,447			668								668	5,779
Ending balance (in shares) at Sep. 30, 2022						57,290,756
Ending balance at Sep. 30, 2022	$ 458,390			313,006		$ 5			424,369		(29,680)	(81,688)	145,384
Beginning balance (in shares) at Dec. 31, 2022	57,723,125					57,723,125
Beginning balance at Dec. 31, 2022	$ 491,452			332,995		$ 6			436,288		(20,677)	(82,622)	158,457
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)	8,424	21,956				8,424
Issuance of common stock upon exercise of options	$ 72			72					72
Issuance of common stock under the equity compensation plan (in shares)						1,069,324	21,956
Stock-based compensation expense	21,381			21,381					21,381
Issuance of common stock, net of issuance costs (in shares)						8,711,250
Issuance of common stock, net of issuance costs	245,832			245,832		$ 1			245,831
Issuance of common stock in connection with acquisitions (in shares)						314,130
Issuance of common stock in connection with acquisitions	9,123			9,123					9,123
Sale of economic interests in majority owned subsidiary, net of taxes	2,217			2,217					2,217				0
Distributions paid to noncontrolling interests	(3,523)			0									(3,523)
Contributions from noncontrolling partner	2,885			0									2,885
Change in cumulative foreign currency translation adjustment	(385)			(385)							(385)
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	2,765			2,765							2,765
Other	(2)			(3)					(2)			(1)	1
Net income (loss)	$ 24,341			4,904								4,904	19,437
Ending balance (in shares) at Sep. 30, 2023	67,848,209					67,848,209
Ending balance at Sep. 30, 2023	$ 796,158			618,901		$ 7			714,910		(18,297)	(77,719)	177,257
Beginning balance (in shares) at Jun. 30, 2023						67,669,564
Beginning balance at Jun. 30, 2023	761,004			593,159		$ 7			703,593		(15,183)	(95,258)	167,845
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of options (in shares)						3,424
Issuance of common stock upon exercise of options	21			21					21
Issuance of common stock under the equity compensation plan (in shares)						3,447	1,871
Stock-based compensation expense	4,326			4,326					4,326
Issuance of common stock, net of issuance costs	(370)			(370)					(370)
Issuance of common stock in connection with acquisitions (in shares)						169,903
Issuance of common stock in connection with acquisitions	5,123			5,123					5,123
Sale of economic interests in majority owned subsidiary, net of taxes	2,217			2,217					2,217
Contributions from noncontrolling partner	2,885			0									2,885
Change in cumulative foreign currency translation adjustment	(4,035)			(4,035)							(4,035)
Change in fair value of cash flow hedge from prior periods reclassified to earnings, net of taxes	921			921							921
Other	0			(1)								(1)	1
Net income (loss)	$ 24,066			17,540								17,540	6,526
Ending balance (in shares) at Sep. 30, 2023	67,848,209					67,848,209
Ending balance at Sep. 30, 2023	$ 796,158			$ 618,901		$ 7			$ 714,910		$ (18,297)	$ (77,719)	$ 177,257